Top Markets
#1 Islamic Coin Islamic Coin +152.58%
#2 Bitway Bitway +44.01%
#3 Starpower Starpower +37.36%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +33.04%
#5 aelf aelf +28.00%
#6 Pons Pons +27.54%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.67%
#8 SkyAI SkyAI +19.06%
#9 Bedrock Bedrock +16.63%
#10 Ocean Protocol Ocean Protocol +16.33%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Kedudukan dalam Saham #29677
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Harga Saham
$0.20877985
Modal Pasaran
$20.11M
Perubahan (1 hari)
-3.03%
Perubahan (1 tahun)
-66.13%
Negara
JP
Perdagangan Modalis Therapeutics Corporation (4883)

Kategori

Healthcare
Pendapatan untuk Modalis Therapeutics Corporation (4883)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Modalis Therapeutics Corporation, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Modalis Therapeutics Corporation dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR